- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05585034
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
November 9, 2023 updated by: Xencor, Inc.
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1, open-label, first-in-human (FIH), multiple-dose, dose escalation study with cohort expansion at the RD, designed to evaluate the safety and tolerability of XmAb808 in combination with pembrolizumab.
This study will be conducted in 2 parts: Part A (dose escalation) and Part B (cohort expansion).
Study Type
Interventional
Enrollment (Estimated)
220
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ben Thompson, MD PhD
- Phone Number: (619) 517-7381
- Email: bthompson@xencor.com
Study Contact Backup
- Name: Amber Sarot
- Phone Number: (858) 245-9419
- Email: asarot@xencor.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Hematology/Oncology
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Sarah Cannon Research Institute at HealthONE
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Recruiting
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute, Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern Memorial Hospital
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irvine Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute, University of Utah
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert Hospital & the Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Part A: Histologically confirmed advanced/metastatic castration-resistant prostate adenocarcinoma, epithelial ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, triple-negative breast cancer, or colorectal cancer that has progressed on standard therapies
- Part B: Histologically confirmed advanced/metastatic castration-resistant prostate cancer that is PD1-naïve; head and neck squamous cell carcinoma that is PD1-naïve or has progressed on prior PD1 therapy; or melanoma that is PD1-naïve or has progressed on prior PD1 therapy
- Measurable disease by RECIST 1.1; subjects with prostate cancer who have evaluable disease according to PCWG3 criteria may enroll
- Life expectancy > 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Key Exclusion Criteria:
- Subjects currently receiving other anticancer therapies
- Any prior treatment with an investigational agent targeting CD28
- History of a life-threatening adverse event related to prior immunotherapy
- Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically and clinically stable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation and Expansion XmAb®808 administered in combination with pembrolizumab
XmAb®808 in combination with pembrolizumab
|
Monoclonal bispecific antibody
Monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 5 years
|
Safety and tolerability as assessed by incidence of TEAEs, including clinically significant changes in safety laboratory tests and clinical findings
|
Up to 5 years
|
Incidence of dose-limiting toxicities (DLTs)
Time Frame: 49 days
|
Safety and tolerability as assessed by incidence of DLTs and all available data which will be used to determine the optimal dose regimen
|
49 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of Cmax
Time Frame: Through study completion, Up to 5 years
|
Peak plasma concentration (Cmax)
|
Through study completion, Up to 5 years
|
Measurement of AUCtau
Time Frame: Through study completion, Up to 5 years
|
Area under the plasma concentration versus time curve (AUCtau)
|
Through study completion, Up to 5 years
|
Objective Response Rate
Time Frame: Through study completion, Up to 5 years
|
Objective response rate by RECIST 1.1 assessment of CT/MRI imaging, as modified by PCWG3 for participants with prostate cancer
|
Through study completion, Up to 5 years
|
Progression-free Survival
Time Frame: Through study completion, Up to 5 years
|
Progression-free survival by RECIST 1.1 assessment of CT/MRI imaging, as modified by PCWG3 for participants with prostate cancer
|
Through study completion, Up to 5 years
|
Duration of Response
Time Frame: Through study completion, Up to 5 years
|
Duration of Response by RECIST 1.1 assessment of CT/MRI imaging, as modified by PCWG3 for participants with prostate cancer
|
Through study completion, Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ben Thompson, MD PhD, Xencor, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 14, 2022
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
October 11, 2022
First Submitted That Met QC Criteria
October 13, 2022
First Posted (Actual)
October 18, 2022
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 9, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Breast Diseases
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Ovarian Neoplasms
- Carcinoma, Squamous Cell
- Breast Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Carcinoma
- Melanoma
- Carcinoma, Ovarian Epithelial
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- XmAb808-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
Clinical Trials on XmAb®808
-
Kowa Research Institute, Inc.Recruiting
-
Xencor, Inc.ICON Clinical ResearchCompletedMelanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditionsUnited States
-
Xencor, Inc.ICON plcActive, not recruitingRenal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditionsUnited States
-
Proteostasis Therapeutics, Inc.Completed
-
MorphoSys AGCompletedNon-Hodgkin LymphomaUnited States, Belgium, Germany, Hungary, Italy, Poland, Spain
-
Proteostasis Therapeutics, Inc.CompletedHealthy Volunteer - Complete | Cystic Fibrosis - CompleteUnited States, Belgium, United Kingdom, France, Germany, Canada, Denmark, New Zealand, Australia
-
Logan College of ChiropracticUnknown
-
Oncternal Therapeutics, IncRecruitingRelapsed/Refractory Aggressive B-Cell MalignanciesUnited States
-
Hadassah Medical OrganizationUnknownDiabetic Foot UlcerIsrael
-
Xijing HospitalUnknownNeurological Rehabilitation | Spinal Cord Injuries | Photobiology | Near Infrared Light IrradiationChina